Vermillion Buys Correlogic's Assets for $435K; Correlogic Settles with LabCorp, Quest | GenomeWeb

This story originally ran on Nov. 9 and has been updated to reflect new information from Vermillion.

By Adam Bonislawski

Vermillion said this week that it has purchased substantially all of Correlogic's assets for $435,000 in cash.

The deal comes as Correlogic has reached an agreement to settle its dispute with Quest Diagnostics and Laboratory Corporation of America regarding rights to its ovarian cancer program.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PLOS this week: transcriptional and translational study of human cytomegalovirus interactions with host cells, spider web DNA study, and more.

The New York Stem Cell Foundation signs a lease for a new space.

Researchers gear up for an international meeting to discuss the ethics of gene editing.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.